{"title":"局部晚期乳腺癌患者对新辅助化疗的反应结果和保乳手术的可行性:前瞻性评估","authors":"Seraj Ahmed, Soham Patra, Nabarun Manna, Santanu Sinha, Tirna Halder","doi":"10.36106/ijsr/2506533","DOIUrl":null,"url":null,"abstract":"Background:Locally advanced breast cancer (LABC) poses a substantial clinical challenge, particularly in regions like India where it accounts for\na signicant proportion of breast cancer cases. Neoadjuvant chemotherapy (NACT) has emerged as a promising strategy to downstage tumors and\nincrease the feasibility of breast conservation surgery (BCS), thus improving patient outcomes. This prospective observational study aimed to\ncomprehensively investigate the clinical characteristics of LABC patients and evaluate the impact of NACT on tumor downstaging and the\nfeasibility of BCS. Methods:Atotal of 100 consecutive female LABC patients (Stage III) aged 25 to 70 years were enrolled in the study. Clinical\nand histopathological data were collected, including age, menstrual status, family history, symptom duration, tumor characteristics, and receptor\nstatus. NACT regimens were administered as per institutional protocols. Tumor and axillary lymph node size changes were measured, and clinical\nresponses were evaluated using RECIST 1.1 criteria. Statistical analyses were conducted using SPSS software. Results: The study population\nexhibited a mean age of 49.43 years, with 61% of patients being premenopausal. The predominant histopathological subtype was invasive ductal\ncarcinoma (91%), and common receptor statuses included ER+ PR+ HER2- (29%) and triple-negative (28%). Post-NACT, 82% of patients\nexhibited a partial response, while 10% achieved a complete response. Notably, BCS feasibility was observed in 60% of cases following NACT.\nHistological subtype and ER/PR status signicantly inuenced response rates (p < 0.05). Conclusion: Neoadjuvant chemotherapy demonstrated\nits efcacy in downstaging LABC tumors, resulting in a higher feasibility of breast conservation surgery. Receptor status emerged as an important\npredictor of chemotherapy response. The study underscores the potential of a multimodal approach involving NACT and BCS to optimize\ntreatment outcomes for LABC patients, particularly in resource-constrained settings.","PeriodicalId":14358,"journal":{"name":"International journal of scientific research","volume":"16 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RESPONSE OUTCOME OF NEO ADJUVANT CHEMO THERAPY AND FEASIBILITY OF BREAST CONSERVATION SURGERY AMONG LOCALLY ADVANCED BREAST CANCER PATIENTS: A PROSPECTIVE EVALUATION\",\"authors\":\"Seraj Ahmed, Soham Patra, Nabarun Manna, Santanu Sinha, Tirna Halder\",\"doi\":\"10.36106/ijsr/2506533\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background:Locally advanced breast cancer (LABC) poses a substantial clinical challenge, particularly in regions like India where it accounts for\\na signicant proportion of breast cancer cases. Neoadjuvant chemotherapy (NACT) has emerged as a promising strategy to downstage tumors and\\nincrease the feasibility of breast conservation surgery (BCS), thus improving patient outcomes. This prospective observational study aimed to\\ncomprehensively investigate the clinical characteristics of LABC patients and evaluate the impact of NACT on tumor downstaging and the\\nfeasibility of BCS. Methods:Atotal of 100 consecutive female LABC patients (Stage III) aged 25 to 70 years were enrolled in the study. Clinical\\nand histopathological data were collected, including age, menstrual status, family history, symptom duration, tumor characteristics, and receptor\\nstatus. NACT regimens were administered as per institutional protocols. Tumor and axillary lymph node size changes were measured, and clinical\\nresponses were evaluated using RECIST 1.1 criteria. Statistical analyses were conducted using SPSS software. Results: The study population\\nexhibited a mean age of 49.43 years, with 61% of patients being premenopausal. The predominant histopathological subtype was invasive ductal\\ncarcinoma (91%), and common receptor statuses included ER+ PR+ HER2- (29%) and triple-negative (28%). Post-NACT, 82% of patients\\nexhibited a partial response, while 10% achieved a complete response. Notably, BCS feasibility was observed in 60% of cases following NACT.\\nHistological subtype and ER/PR status signicantly inuenced response rates (p < 0.05). Conclusion: Neoadjuvant chemotherapy demonstrated\\nits efcacy in downstaging LABC tumors, resulting in a higher feasibility of breast conservation surgery. Receptor status emerged as an important\\npredictor of chemotherapy response. The study underscores the potential of a multimodal approach involving NACT and BCS to optimize\\ntreatment outcomes for LABC patients, particularly in resource-constrained settings.\",\"PeriodicalId\":14358,\"journal\":{\"name\":\"International journal of scientific research\",\"volume\":\"16 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of scientific research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36106/ijsr/2506533\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of scientific research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36106/ijsr/2506533","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
RESPONSE OUTCOME OF NEO ADJUVANT CHEMO THERAPY AND FEASIBILITY OF BREAST CONSERVATION SURGERY AMONG LOCALLY ADVANCED BREAST CANCER PATIENTS: A PROSPECTIVE EVALUATION
Background:Locally advanced breast cancer (LABC) poses a substantial clinical challenge, particularly in regions like India where it accounts for
a signicant proportion of breast cancer cases. Neoadjuvant chemotherapy (NACT) has emerged as a promising strategy to downstage tumors and
increase the feasibility of breast conservation surgery (BCS), thus improving patient outcomes. This prospective observational study aimed to
comprehensively investigate the clinical characteristics of LABC patients and evaluate the impact of NACT on tumor downstaging and the
feasibility of BCS. Methods:Atotal of 100 consecutive female LABC patients (Stage III) aged 25 to 70 years were enrolled in the study. Clinical
and histopathological data were collected, including age, menstrual status, family history, symptom duration, tumor characteristics, and receptor
status. NACT regimens were administered as per institutional protocols. Tumor and axillary lymph node size changes were measured, and clinical
responses were evaluated using RECIST 1.1 criteria. Statistical analyses were conducted using SPSS software. Results: The study population
exhibited a mean age of 49.43 years, with 61% of patients being premenopausal. The predominant histopathological subtype was invasive ductal
carcinoma (91%), and common receptor statuses included ER+ PR+ HER2- (29%) and triple-negative (28%). Post-NACT, 82% of patients
exhibited a partial response, while 10% achieved a complete response. Notably, BCS feasibility was observed in 60% of cases following NACT.
Histological subtype and ER/PR status signicantly inuenced response rates (p < 0.05). Conclusion: Neoadjuvant chemotherapy demonstrated
its efcacy in downstaging LABC tumors, resulting in a higher feasibility of breast conservation surgery. Receptor status emerged as an important
predictor of chemotherapy response. The study underscores the potential of a multimodal approach involving NACT and BCS to optimize
treatment outcomes for LABC patients, particularly in resource-constrained settings.